Currently available GLP-1 options like semaglutide and tirzepatide have demonstrated safety in seniors, with the STEP and SURMOUNT trials including participants up to age 75
Theres also little evidence your skin can absorb any of the ingredients in a meaningful way
This suggests that the addition of glucagon agonism to GIP and/or GLP agonism may result in greater efficacy in people with NAFLD/NASH, Dr
The tolerability profiles of both medications reflect their underlying interactions with gastrointestinal hormone pathways
In preclinical characterization studies (Coskun et al., 2022, Molecular Metabolism), retatrutide demonstrated potent agonist activity at all three target receptors: GIP receptor : High-potency agonism derived from the GIP backbone scaffold
This premium reflects the dual-agonist mechanism, which requires more complex compounding